720-01-4

Basic information

• Product Name: Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate
• Synonyms: 4-Chloro-2-trifluoromethyl-pyrimidine-5-carboxylic acid ethyl ester;Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate 97%;Ethyl4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate97%;4-chloro-6-ethyl-2-(trifluoroMethyl)pyriMidine-5-carboxylate;4-Chloro-5-(ethoxycarbonyl)-2-(trifluoromethyl)pyrimidine, 4-Chloro-5-(ethoxycarbonyl)-2-(trifluoromethyl)-1,3-diazine;Ethyl 4-chloro-2-(trifluoromethyl)-5-pyrimidinecarboxylate;ETHYL 4-CHLORO-2-(TRIFLUOROMETHYL)PYRIMIDINE-5-CARBOXYLATE;BUTTPARK 43\57-70
• CAS NO: 720-01-4
• Molecular Formula: C₈H₆ClF₃N₂O₂
• Molecular Weight: 254.59
• EINECS: 1592732-453-0
• Product Categories: Esters;Pyrazines, Pyrimidines & Pyridazines;Pyrazines, Pyrimidines & Pyridazines;Fluorine series
• Mol File: 720-01-4.mol

Chemical Properties

• Melting Point: 36 °C
• Boiling Point: 95 °C
• Flash Point: 93.292 °C
• Appearance: /
• Density: 1.449 g/cm³
• Vapor Pressure: 0.065mmHg at 25°C
• Refractive Index: 1.466
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.91±0.29(Predicted)
• CAS DataBase Reference: Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate(720-01-4)
• EPA Substance Registry System: Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate(720-01-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39-37/39
• Hazardous Substances Data: 720-01-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate is utilized as a key building block for the synthesis of various pharmaceutical products. Its unique structure and functional groups make it a valuable component in the development of new drugs with diverse therapeutic applications.
Used in Drug Discovery and Development:
Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate is employed in drug discovery and development processes due to its potential biological and pharmacological activities. Its antiviral and anticancer properties are of particular interest, as they may contribute to the creation of novel treatments for viral infections and cancer.
Used in Antiviral Applications:
Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate is studied for its antiviral properties, making it a candidate for the development of antiviral medications. Its specific chemical structure may offer advantages in targeting and inhibiting viral replication or other viral processes.
Used in Anticancer Applications:
Ethyl 4-chloro-2-(trifluoromethyl)pyrimidine-5-carboxylate is also being investigated for its potential anticancer properties, suggesting that it could be a component in the development of new anticancer drugs. Its ability to interact with biological targets related to cancer cell growth and proliferation may contribute to its effectiveness in this area.

InChI:InChI=1/C8H6ClF3N2O2/c1-2-16-6(15)4-3-13-7(8(10,11)12)14-5(4)9/h3H,2H2,1H3

Upstream product

• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 343-67-9 ethyl 2-(trifluoromethyl)-1,6-dihydro-6-oxopyrimidine-5-carboxylate 
• 343-67-9 ethyl 4-hydroxy-2-trifluoromethylpyrimidine-5-carboxylate 

Downstream Products

• 304693-64-9 ethyl 2-(trifluoromethyl)pyrimidine-5-carboxylate 
• 1514-01-8 4-amino-5-(hydroxymethyl)-2-(trifluoromethyl)pyrimidine 
• 141872-40-4 ethyl 2-trifluoromethyl-4-{N-butyl-N-[(2'-[N-triphenylmethyl-1H-tetrazol-5-yl]biphenyl-4-yl)methyl]amino}pyrimidine-5-carboxylate 
• 306960-77-0 2-(trifluoromethyl)pyrimidine-5-carboxylic acid 

Relevant articles and documents

BENZAMIDE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASE CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a benzamide derivative compound, a method for preparing the same, and a pharmaceutical composition for treating or preventing an inflammatory disease containing the same as an active ingredient. The benzamide derivative compound according to the present invention inhibits the expression of PDE4 and regulates the expression of an inflammatory disease-related substance such as IL-4 (interleukin-4), IL-5 (interleukin-4), IFN-γ (interferon-γ), IL-17 (interluekin-17), IgE (immunoglobulin E), and TNF-α (tumor necrosis factor-α), and thus may be utilized as a pharmaceutical composition for treating or preventing an inflammatory disease.

Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis

Selective inhibition of phosphodiesterase (PDE) 4B favorably suppresses the synthesis of inflammatory cytokines and subsequently arrest the development of atopic dermatitis via modulating the intracellular cAMP levels. Considering the side effects of corticosteroids, selective PDE4 inhibition could constitute an effective alternative therapy for the treatment of atopic dermatitis (AD). In this study, a series of novel catechol based compounds bearing pyrimidine as the core have been synthesized and screened for the PDE4 inhibitory properties. The PDE4 selectivity of the active compounds over other PDEs has been investigated. Compound 23 bearing pyrimidine core functionalized with catechol, pyridine and trifluoromethyl groups can effectively inhibit the PDE4B with IC50 value in nanomolar range (IC50 = 15 ± 0.4 nM). Compound 23 exhibited seven fold higher selectivity towards PDE4B over PDE4D. Molecular Docking study confirmed its stronger affinity towards catalytic domain of PDE4B. In-vivo analysis confirmed that compound 23 effectively alleviated the symptoms of atopic dermatitis in DNCB–treated Balb/c mice by suppressing the synthesis of inflammatory mediators such as TNF-α and Ig-E. Taken together, this study suggested that compound 23 could be an effective PDE4 inhibitor for the potential treatment of AD.

Pyrimidinone compounds

Pyrimidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis.

Potent, orally active inhibitors of lipoprotein-associated phospholipase A2: 1-(biphenylmethylamidoalkyl)-pyrimidones

A series of 1-(biphenylmethylamidoalkyl)-pyrimidones has been designed as nanomolar inhibitors of recombinant lipoprotein-associated phospholipase A2 with high potency in whole human plasma. 5-(Pyrazolylmethyl) derivative 16 and 5-(methoxypyrimidinylmethyl) derivative 27 demonstrated excellent pharmacodynamic profiles which correlated well with their pharmacokinetic effects.

Novel inhibitors of AP-1 and NF-κB mediated gene expression: Structure-activity relationship studies of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carb oxylate

In an effort to identify novel inhibitors of AP-1 and NF-κB mediated transcriptional activation, several analogues of ethyl 4-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-2-(trifluoromethyl)pyrimidine-5-carb oxylate (1) were synthesized and tested in two in vitro assays. The 2-(2'-thienyl) substituted compound (11) was identified as the most potent in this series. (C) 2000 Elsevier Science Ltd. All rights reserved.